is waiting for the inflection point
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks. Hey, give CNAT and ACRX a look. After a quick round of DD, I picked up 1K shares of each early in the week. They both have near term catalysts that I am hoping pan out so I can pick up more of our other stock.
Anybody out there? Is there another forum where investors talk out this stock?
What was the volume? I had a couple hundred bucks sitting in both mine and my wife's retirement brokerage accounts, which I are rarely look at, and decided to pick up some shares at .63 right at close.
I share your frustration!
My guess is traders taking profit and moving it to the next biotech with a likely positive binary event.
I believe in general the treatment is usually one cartridge every 24 hours, but I believe I have seen a case study that used a single cartridge for up to 30 hours. In the refractory septic shock study, they employed more aggressive treatment and I believe they swapped out the cartridges every 6 hours. The device retails for $1000.
And of course I failed to mention MM and shorts, but I suspect there is quite a bit of overlap with to 10-20 percent swing traders and the shorts. They gotta make money on the push down also.
Sorry, that is Conatus. Sloppy post while typing at a red light during rush hour.
Look into Cornatus (CNAT). I am an investor. They are wrapping up a phase 2 liver disease/cirrhosis study. Perhaps she could try for compassionate use of their new drug or get in on one of their other phase 2 or pending phase 3 studies.
Lots of possible theories or a combination of them. Perhaps the biotech sector doesn't understand the potential of a device taking the place where drugs are the standard treatment and filling a need where no drugs have been found to work. Perhaps it is a big Biotech/Pharma that wants to keep the price low for a potential future acquisition? Perhaps is is a group a traders that target companies where the share price can easily be manipulated. You don't just make money on increasing share price. You can make money on volatility. If you can easily cause price swings in the 10-20 percent range you have a money making machine. Force the price down to pick up cheap shares, let the price drift back up based the actual merits of the company then take profit. Rinse and repeat. That has been a pattern here for probably about 8 years.
LOL. Yes. I saw those stories. Active lifestyles in more than one way. ; )
Sigh... Take a look a VKTX. Market cap of 1.2 BILLION after good phase TWO results while losing $6+ million per quarter. Meanwhile CTSO has also has a successful phase 2 trial, have started a phase 3 trial, are already approved for sale in 50+ countries, are on the verge of operational profitability but just have a 400 M market cap.
I swear that if this was a drug rather than a device we would be trading 3-4 times higher than we are.
One of our neighbors just moved to the Villages about 6 weeks ago. If you are looking for an active retirement lifestyle, that is the place to go.
I am originally from MA and my wife is from CT. I like the area we are in. Might be a bit boring for some, but some of the top public schools in the state, 5 minutes to the beach and less than an hour drive to Orlando. Most neighbors and friend are somehow involved in the space industry, military or both. Boeing, Lockeed Martin, NASA, ULA, SpaceX, Blue Origin, US Airforce, etc. They are all here.
About 8 miles from Kennedy Space Center.
These hurricanes can surly disrupt your world. hopefully he made out OK. We evacuated for hurricane Matthew 2 years ago and lucked out with just losing a fence. We road out hurricane Irma last year. Lost power for 2 days and water for 9. Got a new roof, pool screen enclosure and pool solar system from insurance out of it though.
Ah. I do think he mentioned one of the Carolinas a few years ago.
You are right, it has been an unusually long time since he has posted anything. I hope it is just a vacation.
His posts tie together. In Acute liver failure Bilirubin levels are elevated. A company trying to develop a liver failure treatment called off their trial. They may have been a possible competitor, as far as the liver failure treatment market is concerned.
It is so close now that the sellers of the 12.50 calls will certainly do what they can to make sure it is under 12.50 on Friday.
Should they test a hypothesis on humans? You need preclinical data for a new indication before you can move on to requesting an IDE from the FDA for a human trial.
As I said, BS. But nothing we can do about it. If you are an investor that has done your DD you should think back to your DD and remember why you invested in this company. Nothing has changed. Purely manipulation going on right now and it is not a new thing either. The tech is solid and it is still just a matter of when not if it goes to next level.
B52,
Two studies are cited in this paper for Cytosorb treatment. A cardiac and a Sepsis study. If you take the time to review the actual data of these studies you will see that the cytokine levels in each of the studies were relatively low to start with. For example I believe the Cardiac trial had IL-6 levels in 100 pg/ml range and in the sepsis trial they topped out at just over 500. Keep in mind that Cytosorb is concentration dependent. The higher the cytokine levels the greater the rate of adsorption. In both these trials the cytokine levels were relatively low compared to many of the other case studies, where positive results were seen, where the levels were in the thousands to tens of thousands pg/ml. These two studies were more like safety studies than efficacy and effectiveness studies as the cytokine levels were just not high enough to even expect a large negative impact from them.
As an analogy, let’s say we want to do a study on the effectiveness of motorcycle helmets preventing brain injury. We have two arms of the study. One with riders who wear helmets and one with riders who do not. If at the end of the study there are no accidents reported and both arms reported no brain injuries, would it be correct to conclude that wearing a motorcycle helmet offers no more protection from brain injury than not wearing one?
Also note that the REFRESH 2 trial, the US phase 3 cardiac trial, is not focused on cytokine reduction but instead on the removal of plasma free hemoglobin, with a hope to reduce the incidents of AKI.
You know that post was 100% sarcasm, right?
No manipulation there. Simply retail investors bailing out and trying to rack up as much commissions charges as possible. LOL.
Sorry, it will post today.
Settlement Date Due Date- 6 p.m. Dissemination Date
August 8/15/2018 8/17/2018 8/24/2018
8/31/2018 9/5/2018 9/12/2018
I see it on the Nasdaq site
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
8/15/2018 2,355,317 295,602 7.967866
7/31/2018 2,405,443 201,584 11.932708
NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then released on a dissemination date after 4 p.m. ET.
September 9/14/2018 9/18/2018 9/25/2018
9/28/2018 10/2/2018 10/9/2018
October 10/15/2018 10/17/2018 10/24/2018
10/31/2018 11/2/2018 11/9/2018
November 11/15/2018 11/19/2018 11/27/2018
11/30/2018 12/4/2018 12/11/2018
December 12/14/2018 12/18/2018 12/26/2018
12/31/2018 1/3/2019 1/10/2019
MM, don't care about what the company does, they just need to make sure there is trading volume. Shorties don't care either, they also make money on the volatility. I would hope karma meets up with them at some point, but unfortunately, if they are making money and the SEC doesn't give a cr@p about these small businesses, they will be laughing all the way to the bank until Cytosorbent hit critical mass/trading volume/market cap where it cannot be manipulated so easily.
More of this cr@p today. MM and shorties need to make their nut. Their nut is made on volatility. With our current trading range and volume, they manufacture the volatility. It sucks, but there is not much you can do about it.
For us retail folks, and the company, it really is BS, because capital raises through ATM or other offerings results in larger dilution than if the price had not been manipulated down.
I looked at the authors other articles and just 5 days ago she published one on CAR T-Cell therapy. How in the world could someone aware of CAR T write an article on Cytosorb and not note the fact that both CAR T and Cytosorb are approved in Europe and Cytosob is a possible treatment for the most serious side effect of CAR T?
Nice exposure, but sparse on details. Unfortunately they ignored the rest of the world and incorrectly made it sound like there would not be much comercialization advancement until the cardiac study is complete in 2020.
A shortcut with the FDA is 3 years instead of 6. With cancer drugs, 8 years instead of 12. EAP denial for Cytosorb was so much BS. The whole EAP program seemed designed for exactly what Cytosorb is.
I didn't see any downgrades. Actually Zacks just raised their share price estimate.
Google 10b5-1 then look at the footnotes on some of the filings. These are programed sales setup with their broker that distances them from executing the actual transactions so that they cannot be accused of making trades based on inside information.
Sample Footnote:
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017 (the "Trading Plan").
On these roller coaster drops you have to ask yourself if it likely due to some adverse event or manipulation? Seeing as there is no pending milestones where bad news may have been leaked my vote is that it is manipulation. Nothing has fundamentally changed with the company to justify the drop.
Could it be shorts driving the price down? Sure. Could it be MM driving the price down to load up? Sure. Could it be an institution holder driving the price down so they can add more? Sure. Sure would be nice to know though, so we could enjoy trading the swings.
Don't know about Monday, but for Cytosorbents success is a "when" question not an "if". IMHO.
Why did I have to mention rollercoaster ; )
Any CAR T news and we are not only solid but moving up to the next level. However, if we don't see any near term catalysts we need to stay aware of the shorties. The share price has a history of being walked down quickly on relatively low volume. Today is a great example.
I have not been following the options for a few months. We have been hovering near 15, so perhaps the sellers of the $15 calls are trying to force the price down to be in a safer position for next Friday. There is not a huge amount of open interest at that strike though.
Ha ha. This investment is not for anyone afraid of rollercoaster rides. When it was trading much lower 10 to 20 percent swings were not unusual.
Let the post-investment conference beat down begin. LOL. And this time it is a double-header...